Alethia Biotherapeutics (Canada), a preclinical-stage biotechnology company focused on bone degredation, closed a $4.7M Series B financing. Participants include AgeChem Venture Fund, BDC Venture Capital and GO Capital.
Collective IP | The World’s Largest Technology Transfer Office Marketplace
Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets
Receive Collective IP Account Access HERE